Pharmacodynamics of Unfractionated Heparin During and After a Hemodialysis Session

American Journal of Kidney Diseases

Volumn 51, Issue 5, 2008, Pages 789-795

  Brunet, Philippe ^a   Simon, Nicolas ^b   Opris, Adriana ^a   Faure, Valérie ^a   Lorec Penet, Anne Marie ^b   Portugal, Henri ^b   Dussol, Bertrand ^a   Berland, Yvon ^a  

^a HÔPITAL DE LA CONCEPTION   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

anti Xa; Anticoagulation; hemodialysis; heparin; nonlinear mixed effects modeling (NONMEM); population pharmacokinetics

Indexed keywords

BLOOD CLOTTING FACTOR 10A; HEPARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CONTINUOUS INFUSION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FRANCE; HEMODIALYSIS; HUMAN; INDIVIDUALITY; MAJOR CLINICAL STUDY; MATHEMATICAL COMPUTING; NONLINEAR SYSTEM; OPTIMAL DRUG DOSE; RISK ASSESSMENT; SIMULATION; THROMBOSIS;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; FACTOR XA; FEMALE; HEPARIN; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 43049109182     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.12.040     Document Type: Article

References (17)

1. Schrader J., Valentin R., Tonnis H.J., et al. Low molecular weight heparin in hemodialysis and hemofiltration patients. Kidney Int 28 (1985) 823-829
2. Guillet B., Simon N., Sampol J.J., et al. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Nephrol Dial Transplant 18 (2003) 2348-2353
3. Boneu B., Caranobe C., Cadroy Y., et al. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit. Semin Thromb Hemost 14 (1988) 18-27
4. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 suppl 3 (2004) S188-S203
5. Goudable C., Ton That H., Damani A., et al. Low molecular weight heparin half life is prolonged in haemodialysed patients. Thromb Res 43 (1986) 1-5
6. Wilhelmsson S., and Lins L.E. Heparin elimination and hemostasis in hemodialysis. Clin Nephrol 22 (1984) 303-306
7. Lim W., Cook D.J., and Crowther M.A. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: A meta-analysis of randomized trials. J Am Soc Nephrol 15 (2004) 3192-3206
8. Sonawane S., Kasbekar N., and Berns J.S. The safety of heparins in end-stage renal disease. Semin Dial 19 (2006) 305-310
9. In: Beal S.L., and Sheiner L.B. (Eds). NONMEM Users Guides (1989-98) (1998), GloboMax LLC, Hanover, MD
10. Farrell P.C., Ward R.A., Schindhelm K., and Gotch F. Precise anticoagulation for routine hemodialysis. J Lab Clin Med 92 (1978) 164-176
11. Smith B.P., Ward R.A., and Brier M.E. Prediction of anticoagulation during hemodialysis by population kinetics and an artificial neural network. Artif Organs 22 (1998) 731-739
12. Ouseph R., Brier M.E., and Ward R.A. Improved dialyzer reuse after use of a population pharmacodynamic model to determine heparin doses. Am J Kidney Dis 35 (2000) 89-94
13. de Swart C.A., Nijmeyer B., Roelofs J.M., and Sixma J.J. Kinetics of intravenously administered heparin in normal humans. Blood 60 (1982) 1251-1258
14. Teien A.N., and Bjoornson J. Heparin elimination in uraemic patients on haemodialysis. Scand J Haematol 17 (1976) 29-35
15. Kandrotas R.J., Gal P., Douglas J.B., and Deterding J. Pharmacokinetics and pharmacodynamics of heparin during hemodialysis: Interpatient and intrapatient variability. Pharmacotherapy 10 (1990) 349-355
16. Ouseph R., and Ward R.A. Anticoagulation for intermittent hemodialysis. Semin Dial 13 (2000) 181-187
17. Mingardi G., Perico N., Pusineri F., et al. Heparin for hemodialysis: Practical guidelines for administration and monitoring. Int J Artif Organs 7 (1984) 269-274